GLUE — Monte Rosa Therapeutics, Inc.
—
Nasdaq ·
Health Care ·
Biotechnology ·
CIK 1826457 ·
Last close
$18.12
Market Cap
$1.53B
52W High
$21.62
52W Low
$14.20
ADV30
883,727
Next earnings
2026-08-06
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 4,210,000 | — | -50,034,000 | -44,503,000 | 736,428,000 | 159,859,000 | 214,512,000 |
| Dec 2025 | 2,781,000 | — | -49,715,000 | -46,135,000 | 448,659,000 | 129,883,000 | 215,603,000 |
| Sep 2025 | 12,768,000 | — | -32,975,000 | -27,081,000 | 459,841,000 | 208,343,000 | 214,004,000 |
| Jun 2025 | 23,194,000 | — | -15,554,000 | -12,295,000 | 359,586,000 | 69,429,000 | 91,506,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-22,798,000
Investing CF
$-101,833,000
Financing CF
$30,351,000
CapEx
$-4,700,000
Dividends Paid
—
Buybacks
$-357,000
EPS Diluted TTM
$-0.77
As of
2026-05-10
Balance + Analyst (yfinance extras)
Retained Earnings
$-477,214,000
Inventory
—
Receivables
$11,600,000
ST Investments
$247,221,000
EBIT TTM
$-54,208,000
Pretax Income TTM
$-39,723,000
Interest Exp TTM
—
Analysts
6
Yahoo Snapshot (yfinance, live)
Total Revenue
$42,953,000
EBITDA
$-139,940,992
Free Cash Flow
$-77,161,752
Enterprise Value
$903,611,072
Total Cash
$666,220,032
Total Debt
$39,064,000
Shares Out
84,479,418
Trailing EPS
$-1.48
Book Value
$6.19
ROE
-32.6%
ROA
-16.4%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 123,672,000 | -54,208,000 | -38,626,000 | 448,659,000 | 215,603,000 | — | -22,798,000 |
| Dec 2024 | 75,622,000 | -81,112,000 | -72,700,000 | 438,732,000 | 215,796,000 | — | 41,996,000 |
| Dec 2023 | 0 | -143,311,000 | -135,352,000 | 303,755,000 | 124,505,000 | — | -43,802,000 |
| Dec 2022 | 0 | -112,384,000 | -108,501,000 | 342,389,000 | 70,976,000 | — | -92,466,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-1.81
Max Pain — expiry 2026-06-18
max pain strike: $20.00 · spot: $17.76 · call oi: 1,519 · put oi: 27
Expected Move to 2026-06-18:
±$4.62
(26.01%) —
implied range
$13.14 –
$22.38
· ATM straddle on $17.50 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| NVAX | NOVAVAX INC | $1.51B | $9.21 | — |
| IMCR | Immunocore Holdings plc | $1.46B | $28.63 | — |
| VIR | Vir Biotechnology, Inc. | $1.45B | $8.61 | — |
| INBX | Inhibrx Biosciences, Inc. | $1.37B | $93.51 | — |
| TSHA | Taysha Gene Therapies, Inc. | $1.72B | $5.97 | — |
News headlines (Yahoo Finance, 1h cache)
Monte Rosa Therapeutics (GLUE): Best Growth Stocks Under $20 to Buy
2026-06-03 18:00 · Yahoo
Monte Rosa Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2026-06-02 20:01 · Yahoo
Monte Rosa Therapeutics to Participate in Upcoming Investor Conferences
2026-05-20 11:00 · Yahoo
Monte Rosa Trial Progress And Valuation Gap Draw Investor Attention
2026-05-10 00:24 · Yahoo
Monte Rosa Therapeutics (GLUE) Reports Q1 Loss, Misses Revenue Estimates
2026-05-07 15:15 · Yahoo
Monte Rosa Therapeutics Announces First Quarter 2026 Financial Results and Business Updates
2026-05-07 11:00 · Yahoo
Myriad Genetics (MYGN) Reports Q1 Loss, Misses Revenue Estimates
2026-05-06 00:30 · Yahoo
Monte Rosa CEO Sells $141K in Stock Amid 300% Surge and Recent Capital Raise
2026-04-21 17:53 · Yahoo
Monte Rosa Therapeutics Presents Preclinical Data at American Association for Cancer Research (AACR) Annual Meeting 2026 on the Potential of its Cyclin E1 (CCNE1)-directed Molecular Glue Degrader to T
2026-04-20 11:00 · Yahoo
Monte Rosa J J Supply Deal Refocuses MRT 2359 Prostate Cancer Story
2026-03-21 11:07 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.